These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34766004)

  • 41. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Front Mol Biosci; 2022; 9():781039. PubMed ID: 35359601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery.
    Zhao Z; Bourne PE
    J Proteome Res; 2020 Nov; 19(11):4698-4705. PubMed ID: 32946692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
    Begum F; Srivastava AK; Ray U
    Biochem Biophys Res Commun; 2021 Sep; 571():26-31. PubMed ID: 34303192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug repositioning against COVID-19: a first line treatment.
    Bibi N; Farid A; Gul S; Ali J; Amin F; Kalathiya U; Hupp T
    J Biomol Struct Dyn; 2022; 40(23):12812-12826. PubMed ID: 34519259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles.
    Rabie AM
    Chem Biol Interact; 2021 Jul; 343():109480. PubMed ID: 33887223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2.
    Ahmed S; Mahtarin R; Ahmed SS; Akter S; Islam MS; Mamun AA; Islam R; Hossain MN; Ali MA; Sultana MUC; Parves MR; Ullah MO; Halim MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6290-6305. PubMed ID: 32720571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
    Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
    Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
    Wakchaure PD; Ghosh S; Ganguly B
    J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19.
    Rabie AM
    Curr Res Pharmacol Drug Discov; 2021; 2():100055. PubMed ID: 34870153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
    Khursheed A; Jain V; Rasool A; Rather MA; Malik NA; Shalla AH
    Microb Pathog; 2021 Aug; 157():104933. PubMed ID: 33984466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
    Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Singh P; Tripathi MK; Yasir M; Khare R; Shrivastava R
    Mol Biol Res Commun; 2021 Sep; 10(3):131-140. PubMed ID: 34476266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
    Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study.
    Rabie AM; Abdalla M
    ChemistrySelect; 2022 Dec; 7(46):e202201912. PubMed ID: 36718467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes.
    Shaldam MA; Yahya G; Mohamed NH; Abdel-Daim MM; Al Naggar Y
    Environ Sci Pollut Res Int; 2021 Aug; 28(30):40507-40514. PubMed ID: 33934306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
    Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
    Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.